Testing NTX-253 in healthy people and those with stable schizophrenia
Part of Mental health clinical trials.
This trial is testing a new medicine, NTX-253, to see how safe it is and how the body processes it. It is for healthy adults and adults with schizophrenia whose symptoms are stable on their current treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 55 years old.
- You are a healthy adult, or you have stable schizophrenia (not resistant to treatment).
- You haven't had cancer treated in the last 7 years.
- You do not have serious stomach or gut problems that could affect how the drug is absorbed.
- You agree to use effective birth control if you are able to have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, NBI-1117568, to see if it can help prevent a relapse of schizophrenia symptoms. It is for adults who have been stable on other antipsychotics and want to avoid returning to the hospital for a psychiatric stay.
This trial tests an investigational medicine called NTX-1472 to see if it helps people with social anxiety disorder. Participation involves taking the study drug and attending scheduled visits.
This trial tests whether adding NaBen (a supplement-like medicine) to clozapine can improve “residual” symptoms in adults with difficult-to-treat schizophrenia. The study also checks safety and the best dose, using a placebo (inactive pill) for comparison.
This trial tests an experimental medicine, LTX-001, for people with schizophrenia who are currently having a sudden worsening of symptoms. It aims to see if the drug can help reduce these acute symptoms.
This study tests a new medicine, KR23248, in healthy people to see if it is safe and how the body handles it. It is a first-in-human trial, so the main goal is to find out about side effects and how the drug moves through the body.
This trial tests a new drug, GXV813, to see if it helps reduce symptoms in people with schizophrenia who are currently hospitalized due to a sudden worsening of their condition. It compares the drug's safety and effect against a placebo over several weeks.
Hear when a new Healthy Participants trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.